# Deficiency of Tissue Nonspecific Alkaline Phosphatase Dysregulates Microglial Morphology and Function in a Mouse Model of Infantile Hypophosphatasia

**Authors:** Kareem Elaswad, Yara Mashal, Iyah Nasser, Linna Almhanaa, Chloe Grabowski, Zhi Zhang

PMC · DOI: 10.1111/jnc.70398 · 2026-03-06

## TL;DR

This study shows that a lack of TNAP in mice leads to microglial changes and health issues, suggesting TNAP is important for brain function and disease prevention.

## Contribution

The study reveals TNAP's role in regulating microglial morphology, metabolism, and signaling in a sex- and cell-specific manner.

## Key findings

- TNAP deficiency causes microglial morphological changes like enlarged cell bodies and shortened processes.
- Loss of TNAP shifts microglial metabolism toward neurotoxicity and increases neuroinflammatory and senescence markers.
- TNAP depletion in microglia alters purinergic signaling and modulates inflammatory responses.

## Abstract

Tissue‐nonspecific alkaline phosphatase (TNAP) has emerged as a crucial regulator of neuronal circuit formation and maintenance; however, the complexities of its sex‐ and cell type‐specific roles within microglia remain largely unexplored. To address this critical knowledge gap, this study examined how TNAP deficiency differentially affects microglial morphology, function, and signaling in both male and female mice, and investigated its broader implications for neurodevelopment and disease susceptibility. Using Alpl

+/+
 (wild‐type) and Alpl

−/−
 (TNAP knockout) mice, we conducted behavioral assessments at postnatal Days 13–14 to evaluate early neurobehavioral outcomes. Microglia were subsequently isolated for molecular, metabolic, and morphological analyses. TNAP‐deficient mice of both sexes exhibited profound physiological deficits, including stunted growth and significant sensorimotor impairments, confirming effective TNAP knockout and indicating that systemic TNAP loss affects multiple cell types beyond microglia. At the cellular level, TNAP loss induced notable morphological changes in microglia, characterized by enlarged cell soma and shortened processes, hallmarks of microglial activation. Molecular profiling revealed upregulation of neuroinflammatory and phagocytic markers, implicating TNAP as a modulator of the innate immune response. Furthermore, metabolic analyses uncovered a dramatic shift in tryptophan‐kynurenine metabolism, with increased quinolinic acid production signifying a transition to a neurotoxic, pro‐inflammatory state. Additionally, TNAP‐deficient microglia displayed extensive dysregulation in purinergic signaling pathways, exemplified by increased expression of key purinergic receptors, and acquired a senescent phenotype evidenced by elevated canonical senescence gene expression. Given the influence of TNAP deficiency on multiple cell populations, some observed microglial phenotypes may result from altered intercellular signaling or indirect effects. To delineate cell‐autonomous effects, siRNA‐mediated TNAP knockdown was performed in primary microglia isolated from wild‐type (WT) mice. TNAP depletion modulated inflammatory responses, suggesting an intrinsic role for TNAP in microglial regulation; however, these effects may not fully recapitulate the extent of deficiency observed in vivo. Overall, TNAP emerges as a key modulator of microglial structure and function, with its dysfunction potentially increasing susceptibility to neurodevelopmental and neurodegenerative disorders. This highlights the potential of TNAP as a therapeutic target for central nervous system health and disease.

Using male and female tissue‐nonspecific alkaline phosphatase (TNAP) knockout (KO) and wild type (WT) mice, we show TNAP loss impairs growth and sensorimotor function and induces marked microglial morphological changes (enlarged soma, retracted processes). TNAP‐deficient microglia upregulate neuroinflammatory, phagocytic, and senescence markers; shift kynurenine metabolism toward neurotoxicity; and exhibit dysregulated purinergic signaling. These findings reveal TNAP as a key regulator of microglial structure, metabolism, and homeostasis, with broad implications for central nervous system (CNS) health and disease.

## Linked entities

- **Genes:** ALPL (alkaline phosphatase, biomineralization associated) [NCBI Gene 249]
- **Proteins:** ALPL (alkaline phosphatase, biomineralization associated)
- **Chemicals:** tryptophan (PubChem CID 1148), kynurenine (PubChem CID 846)
- **Diseases:** infantile hypophosphatasia (MONDO:1010169)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Cdkn1a (cyclin dependent kinase inhibitor 1A) [NCBI Gene 12575] {aka CAP20, CDKI, CIP1, Cdkn1, P21, SDI1}, Spp1 (secreted phosphoprotein 1) [NCBI Gene 20750] {aka 2AR, Apl-1, BNSP, BSPI, Bsp, ETA-1}, P2ry12 (purinergic receptor P2Y, G-protein coupled 12) [NCBI Gene 70839] {aka 2900079B22Rik, 4921504D23Rik, P2Y12}, P2rx7 (purinergic receptor P2X, ligand-gated ion channel, 7) [NCBI Gene 18439] {aka P2X(7), P2X7R}, Gapdh (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 14433] {aka Gapd}, Nlrp3 (NLR family, pyrin domain containing 3) [NCBI Gene 216799] {aka AGTAVPRL, AII/AVP, Cias1, FCAS, FCU, MWS}, Nos2 (nitric oxide synthase 2, inducible) [NCBI Gene 18126] {aka MAC-NOS, NOS-II, Nos-2, Nos2a, i-NOS, iNOS}, Csf2 (colony stimulating factor 2 (granulocyte-macrophage)) [NCBI Gene 12981] {aka CSF, Csfgm, GMCSF, Gm-CSf, MGI-IGM}, Csf1 (colony stimulating factor 1 (macrophage)) [NCBI Gene 12977] {aka BAP025, Csfm, MCSF, Mhdabap25, PG-M-CSF, op}, Ido1 (indoleamine 2,3-dioxygenase 1) [NCBI Gene 15930] {aka Ido, Indo}, Trem2 (triggering receptor expressed on myeloid cells 2) [NCBI Gene 83433] {aka TREM-2, Trem2a, Trem2b, Trem2c}, Qprt (quinolinate phosphoribosyltransferase) [NCBI Gene 67375] {aka 2410027J01Rik, QPRTase}, Aif1 (allograft inflammatory factor 1) [NCBI Gene 11629] {aka AIF-1, D17H6S50E, G1, Iba1}, Tgfb1 (transforming growth factor, beta 1) [NCBI Gene 21803] {aka TGF-beta1, TGFbeta1, Tgfb, Tgfb-1}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, Alpl (alkaline phosphatase, liver/bone/kidney) [NCBI Gene 11647] {aka ALP, APTNAP, Akp-2, Akp2, TNAP, TNSALP}, Il6 (interleukin 6) [NCBI Gene 16193] {aka Il-6}, Trp53-ps (transformation related protein 53, pseudogene) [NCBI Gene 22060], P2ry6 (pyrimidinergic receptor P2Y, G-protein coupled, 6) [NCBI Gene 233571] {aka 2010204J23Rik, P2Y6}, Il18 (interleukin 18) [NCBI Gene 16173] {aka Igif, Il-18}, Kmo (kynurenine 3-monooxygenase) [NCBI Gene 98256], Haao (3-hydroxyanthranilate 3,4-dioxygenase) [NCBI Gene 107766] {aka 0610007K21Rik, 0610012J07Rik, 3-HAO, 3-HAOxase, 3HAO}, Kcnk13 (potassium channel, subfamily K, member 13) [NCBI Gene 217826] {aka F730021E22Rik, Gm1570, Gm1685}, App (amyloid beta precursor protein) [NCBI Gene 11820] {aka Abeta, Abpp, Adap, Ag, Cvap, E030013M08Rik}, Sting1 (stimulator of interferon response cGAMP interactor 1) [NCBI Gene 72512] {aka 2610307O08Rik, ERIS, MPYS, Mita, STING, STING-beta}, Kynu (kynureninase) [NCBI Gene 70789] {aka 4432411A05Rik}, Cd68 (CD68 antigen) [NCBI Gene 12514] {aka Lamp4, Scard1, gp110}, Tlr4 (toll-like receptor 4) [NCBI Gene 21898] {aka Lps, Ly87, Ran/M1, Rasl2-8}, C3 (complement component 3) [NCBI Gene 12266] {aka ASP, HSE-MSF, Plp}, Il1b (interleukin 1 beta) [NCBI Gene 16176] {aka IL-1beta, Il-1b}, Cyp2b10 (cytochrome P450, family 2, subfamily b, polypeptide 10) [NCBI Gene 13088] {aka Cyp2b, Cyp2b20, p16}, Iba1 (induction of brown adipocytes 1) [NCBI Gene 114737]
- **Diseases:** HPP (MESH:D007014), Developmental delays (MESH:D002658), amyloid (MESH:C000718787), depression (MESH:D003866), inflammatory cytokines (MESH:D000080424), Whyte (MESH:C535783), Failure to Thrive and (MESH:D005183), impaired mobility (MESH:D014086), inherited metabolic disorder (MESH:D020739), death (MESH:D003643), epileptic seizures (MESH:D004827), neurological disorders (MESH:D009461), odontohypophosphatasia (MESH:C564146), seizures (MESH:D012640), respiratory arrest (MESH:D012131), sensorimotor deficits (MESH:D020233), anxiety (MESH:D001007), Neuroinflammation (MESH:D000090862), muscle weakness (MESH:D018908), AD (MESH:D000544), neurotoxic (MESH:D020258), muscle strength (MESH:D019042), stunted growth (MESH:D006130), pain (MESH:D010146), sleeping disorders (MESH:D012893), TNAP Deficiency (MESH:D016585), neurodevelopmental and neurodegenerative disorders (MESH:D019636), Inflammatory (MESH:D007249)
- **Chemicals:** ice (MESH:D007053), Ca (MESH:D002118), formalin (MESH:D005557), serotonin (MESH:D012701), DAPI (MESH:C007293), Tryptophan (MESH:D014364), pyridoxal-5'-phosphate (MESH:D011732), DAB (MESH:C000469), vitamin B6 (MESH:D025101), 3,3'-diaminobenzidine (MESH:D015100), dopamine (MESH:D004298), purine (MESH:C030985), LPS (MESH:D008070), pyrophosphate (MESH:C107241), sucrose (MESH:D013395), CO2 (MESH:D002245), L-Glutamine (MESH:D005973), ATP (MESH:D000255), Lipofectamine (MESH:C086724), K+ (MESH:D011188), Halothane (MESH:D006221), hydrogen peroxide (MESH:D006861), DS (MESH:D003903), Fluriso (-), QA (MESH:D017378), kynurenine (MESH:D007737), glutamate (MESH:D018698), GABA (MESH:D005680), TRIZOL (MESH:C411644), Isoflurane (MESH:D007530), gliotoxin (MESH:D005912), adenosine phosphates (MESH:D000227), pyridoxine (MESH:D011736), adenosine (MESH:D000241)
- **Species:** Homo sapiens (human, species) [taxon 9606], Rodentia (rodent, order) [taxon 9989], Rattus norvegicus (brown rat, species) [taxon 10116], Mus musculus (house mouse, species) [taxon 10090]
- **Mutations:** C-22 C
- **Cell lines:** C57BL/6 — Mus musculus (Mouse), Transformed cell line (CVCL_C0MU), Alpl.13.3 — Mus musculus (Mouse), Hybridoma (CVCL_C3WC)

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12966415/full.md

---
Source: https://tomesphere.com/paper/PMC12966415